Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 14, 2015 - Issue 6
Submit an article Journal homepage
7,177
Views
66
CrossRef citations to date
0
Altmetric
Editorial

Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events

Daisuke YabeKansai Electric Power Hospital, Center for Diabetes, Endocrinology and Metabolism, 2-1-7 Fukushima-ku, Osaka 553-0003, Japan+81 6 6458 5821; +81 6 6458 6994; [email protected]; [email protected];Kansai Electric Power Hospital, Center for Metabolism and Clinical Nutrition, 2-1-7 Fukushima-ku, Osaka 553-0003, Japan;Kobe University Graduate School of Medicine, Department of Physiology and Cell Biology, Division of Molecular and Metabolic Medicine, 1-5-6 Minatojimaminamimachi, Chuo-ku, Kobe 650-0047, Japan
,
Rie NishikinoJapan Medical Data Center Co., Ltd., Sumitomo Shibadaimon Building 12F, 2-5-5 Shibadaimon, Minato-ku, Tokyo 105-0012, Japan
,
Makiko KanekoJapan Medical Data Center Co., Ltd., Sumitomo Shibadaimon Building 12F, 2-5-5 Shibadaimon, Minato-ku, Tokyo 105-0012, Japan
,
Masahiro IwasakiKansai Electric Power Hospital, Center for Metabolism and Clinical Nutrition, 2-1-7 Fukushima-ku, Osaka 553-0003, Japan
&
Yutaka SeinoKansai Electric Power Hospital, Center for Diabetes, Endocrinology and Metabolism, 2-1-7 Fukushima-ku, Osaka 553-0003, Japan+81 6 6458 5821; +81 6 6458 6994; [email protected]; [email protected]
Pages 795-800 | Published online: 07 Apr 2015

Bibliography

  • Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig 2014;5(3):265-75
  • Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2014;104(3):297-322
  • Tauchi K. 10 deaths reported following use of newly marketed diabetes drugs. Available from: http://ajw.asahi.com/article/sci_tech/medical/AJ201501090058 [Last accessed 17 January 2015]
  • Hoffman KB, Dimbil M, Erdman CB, et al. The Weber effect and the United States food and drug administration’s adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug safety 2014;37(4):283-94
  • Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159(4):262-74
  • Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabet Investig 2014;5(5):475-7
  • Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124(2):499-508
  • Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104(6):787-94
  • Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012;122(1):4-12
  • Yabe D, Kuroe A, Watanabe K, et al. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. J Diabetes Complications 2015;29(3):413-21
  • Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124(2):509-14
  • Yabe D, Seino Y, Fukushima K, et al.β-cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Current Diabetes Report; 10.1007/s11892-015-0602-9
  • Dimitriadis G, Mitrou P, Lambadiari V, et al. Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract 2011;93(Suppl 1):S52-9
  • Ramnanan CJ, Edgerton DS, Kraft G, et al. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 2011;13(Suppl 1):118-25
  • Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol 2014;2(10):819-29

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.